AIM ImmunoTech Inc (AIM) Quote

They're steadily sliding down, but it might still make sense to monitor the situation for a while. Equels Thomas has made modest investments in his company’s stock this year—here’s the insider trading stats for reference: https://prismo.pro/stock/aim. Regardless, shares are purchased with the aim of yielding profit. Could it be they’re preparing for one of their drugs to finally hit the mark?

News is out

Guys what is the potential on this company?

AIM
AIM ImmunoTech Inc
0.265
-0.0508 (-16.09%)
Volume: 527,731
Day Range: 0.261 - 0.3223
Last Trade Time: 12:49:35 PM EDT
Total Trades: 888

AIM new 52 week low

AIM new 52 week low

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

https://otcbb.swingtradebot.com/equities/AIM

AIM
AIM ImmunoTech Inc
0.67
0.052 (8.41%)
Volume: 150,500
Day Range: 0.607 - 0.68
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.488
-0.032 (-6.15%)
Volume: 176,585
Day Range: 0.48 - 0.5387
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.4784
0.00 (0.00%)
Volume: 61,433
Day Range: 0.475 - 0.50
Last Trade Time: 8:00:00 PM EDT

https://www.otcmarkets.com/stock/AIM

AIM
AIM ImmunoTech Inc
0.5063
0.0263 (5.48%)
Volume: 62,250
Day Range: 0.47 - 0.49
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.47
0.029 (6.58%)
Volume: 26,623
Day Range: 0.4301 - 0.4586
Last Trade Time: 8:00:00 PM EDT

AIM
AIM ImmunoTech Inc
0.53
0.035 (7.07%)
Volume: 292,608
Day Range: 0.4916 - 0.55
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST

They have one fda approved drug patent has expired and Ampligen has been denied by fda. This is a good one one to get in after the rs and wait for the bottom. Just like Maple oil

This company looks like they have some good potential. I recently watched a doctor from Canada who is convinced by her teams studies that the Covid vaccines cause damage to TLRs 3,7, and 8 causing people to be more susceptible to illness. Their TLR 3 nasal spray might be extremely helpful in this case.

AIM
AIM ImmunoTech Inc
0.34
-0.0067 (-1.93%)
Volume: 196,446
Day Range: 0.322 - 0.35
Last Trade Time: 8:00:00 PM EST

AIM
AIM ImmunoTech Inc
0.6286
0.0708 (12.69%)
Volume: 176,005
Day Range: 0.5678 - 0.5797
Last Trade Time: 8:00:00 PM EDT
Total Trades: 323
AIM Detailed Quote

AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote

This is the AIM I see...

AIM
Bid: 0.70 Ask: 0.7089 Last: 0.7001 Chg ($): -0.0025 Vol: 20.03K
https://finviz.com/quote.ashx?t=AIM

dis is good stuff Phase 2 Study of Ampligen®

Aug-18-22 09:05AM
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
GlobeNewswire
Aug-16-22 04:05PM
AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation
GlobeNewswire
-5.50%
Aug-15-22 04:05PM
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
Business Wire
08:05AM
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
GlobeNewswire

AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote

lot in pipeline too

Haven't even really started my DD and the first thing that caught my eye was drama!


Quote:
“The actions of AIM are a desperate attempt and part of a troubling pattern of
AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth

wasting corporate assets at the expense of stockholders to do whatever it takes
to ensure that they run unopposed, including crafting up ‘conspiracy theories’ in

their effort to retain control and enrich themselves and deny stockholders basic rights to nominate alternative directors,
solely to keep their gravy-train of excessive compensation going,
” stated Mr. Jorgl. “

We are very pleased that the court has set the earliest date possible for expedited proceedings on our matter, which we expect will result in our nominations being allowed.”

https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html


This could get interesting. Going to do some digging and put this on radar.

Just stumbled on this one Mick.

Haven't even really started my DD and the first thing that caught my eye was drama!

“The actions of AIM are a desperate attempt and part of a troubling pattern of AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth wasting corporate assets at the expense of stockholders to do whatever it takes to ensure that they run unopposed, including crafting up ‘conspiracy theories’ in their effort to retain control and enrich themselves and deny stockholders basic rights to nominate alternative directors, solely to keep their gravy-train of excessive compensation going,” stated Mr. Jorgl. “We are very pleased that the court has set the earliest date possible for expedited proceedings on our matter, which we expect will result in our nominations being allowed.”
https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html


This could get interesting. Going to do some digging and put this on radar.

AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series • GlobeNewswire Inc. • 07/14/2022 12:05:00 PM
Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 07/01/2022 08:32:31 PM
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing • GlobeNewswire Inc. • 06/21/2022 12:35:00 PM

AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote

Stop loss done pumpit Friday.

Stop loss done pumpit Friday.

AIM ImmunoTech Inc (AIM)
0.94 ? 0.02 (2.17%)
Volume: 49,334 @06/03/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 0.91 - 0.93
AIM Detailed Quote

AIM ImmunoTech Inc (AIM)
1.06 ? 0.01 (0.95%)
Volume: 115,978 @04/29/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.03 - 1.08
AIM Detailed Quote

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided a summary of clinical data that support the synergistic potential of Ampligen® (rintatolimod) with checkpoint blockade therapies.
Thomas Equels, Chief Executive Officer of AIM, commented, “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions. These data have not only affirmed but significantly evolved our belief that Ampligen as a single agent therapy, as well as in combination with the latest powerful cancer therapies, has the potential to become a breakthrough therapy for some of the most difficult to treat and deadly cancers. We are going to continue working tirelessly to advance Ampligen towards approval and commercialization with the goal of bringing much needed hope to patients and solutions to treating physicians around the world.”

Ampligen is the Company’s dsRNA drug currently being developed for globally important cancers. Ampligen has shown therapeutic synergy with checkpoint inhibitors, including increasing survival rates and efficacy, in the treatment of animal tumors when used in combination with checkpoint blockade therapies. The first detection of Ampligen’s synergistic potential with checkpoint blockade therapeutics was witnessed in pre-clinical mouse models of melanoma and pancreatic cancers. Additionally, the Company now has data from two clinical studies — in advanced recurrent ovarian cancer and triple negative breast cancer — that indicate that the drug may have similar anti-tumor activity in humans.

“Working with AIM, our Pancreatic Cancer R&D team at the Buffett Cancer Center did extensive pre-clinical research demonstrating in animal models that Ampligen had a significant therapeutic benefit in treating pancreatic cancer. This March, Prof. C.H.J. van Eijck and his team at Erasmus MC published data in the journal Cancers showing Ampligen alone was associated with extended overall survival in late-stage pancreatic cancer of 19 months. Just last week, at AACR, publications of clinical data by UPMC’s Dr. Bob Edwards in advanced recurrent ovarian cancer, and Roswell’s Dr. Pawel Kalinski in both stage 4 triple negative breast cancer and stage 4 colorectal cancer, strongly supported the advance of Ampligen into human trials for patients in pancreatic and other cancers where checkpoint drugs are not effective,” stated Michael (Tony) Hollingsworth, PhD, Associate Director, Basic Research, University of Nebraska Medical Center.

“Checkpoint drugs are powerful and important therapies, but only work on ‘hot’ tumors visible to the immune system, not ‘cold’ tumors that are immune-silent. Ampligen appears, from these data, to turn cold tumors into hot tumors and create significant therapeutic potential for a successful second round of Ampligen plus checkpoint therapy for those who do not respond to checkpoint therapy alone,” added Robert Edwards, MD, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute.

“The two ongoing Roswell Park clinical trials we recently presented findings from represent milestones in our 10-year-long NIH and DoD-funded research program aiming to convert immuno-resistant ‘cold’ tumors into ‘hot’ ones that would be more sensitive to immunotherapy. Seeing both studies successfully meet their predetermined efficacy endpoint — selective increase of cytotoxic T lymphocyte markers in tumor tissues — Roswell Park plans to move forward with critical studies assessing therapeutic efficacy of the combination of a rintatolimod-based chemokine-modulating regimen with PD-1 inhibitors, cancer vaccines and/or adoptive T cell therapies in solid tumors. Observations from our preclinical studies suggest that this multipronged strategy may benefit patients with multiple solid-tumor lesions, which are difficult to target individually,” commented Pawel Kalinski, MD, PhD, Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science at, Roswell Park Comprehensive Cancer Center.

Recurrent Ovarian Cancer: ClinicalTrials.gov: NCT03734692

The investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (KEYTRUDA®) (IVP) for patients with recurrent platinum-sensitive ovarian cancer is being conducted by the University of Pittsburgh Medical Center (UPMC). The Phase 2 trial is designed to enroll up to 45 subjects using Ampligen in combination with pembrolizumab to test the combinational activity of checkpoint blockade therapy where Ampligen is administered by injection in the peritoneal cavity where the tumor is located.

The Company’s recently announced positive interim results suggesting induction of T cell activation together with clinical responses may indicate prognostic evidence of tumor environment reprogramming that we do not see with chemotherapy alone and which may extend survival. A total of 17 patients have been enrolled and 13 were evaluable for response in the ongoing Phase 2 trial. The observed clinical responses were: 2 complete responses (15.4%), 3 partial responses (23.1%), 3 stable disease (23.1%), 5 progressions (38.4%) for a clinical benefit rate (CR+PR+SD) of 61.6%. From 13 patients, 77 IP wash samples were collected at serial time points. Measurements in IP washes revealed an acute increase in granzyme B (GZMB), perforin, TNF alpha, CXCL9, CXCL10 and CXCL11 after treatment (p<0.05). Longitudinal data revealed a progressive increase in some biomarkers in the locoregional environment; CXCL9, CXCL10, CXCL11, perforin and TNF alpha were all increased from baseline levels at cycle 1 to baseline of cycle 6 (p<0.05). CXCL12 was also increased acutely after treatment (p<0.05).

The cytokine CXCL12 observed to increase acutely after treatment functions as a chemotactic for lymphocytes. The cytokines CXCL9-11 active in antitumor responses in modulation of the tumor microenvironment (TME) to favor cytotoxic T cells required for anti-tumor cell immune activity versus regulatory T cells (Tregs), which function to protect non-tumor “self” tissue. Granzymes are serine proteases released by cytoplasmic granules within cytotoxic T cells and natural killer (NK) cells. They induce programmed cell death (apoptosis) in the target cell, eliminating cells that have become cancerous. Perforin is a protein, which creates tubules in the cell membrane allowing cell lysis. Perforin is a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.

https://www.otcmarkets.com/stock/AIM

AIM ImmunoTech Inc (AIM)
0.839899 ? -0.000001 (-0.00%)
Volume: 152,721 @03/11/22 8:00:00 PM EST
Bid Ask Day's Range
- - 0.8054 - 0.86
AIM Detailed Quote

AIM ImmunoTech Inc (AIM)
0.79 ? 0.0109 (1.40%)
Volume: 85,652 @02/04/22 8:00:00 PM EST
Bid Ask Day's Range
- - 0.789951 - 0.8191
AIM Detailed Quote

https://www.otcmarkets.com/stock/AIM

https://www.otcmarkets.com/stock/AIM

AIM ImmunoTech Inc (AIM)
1.77 ? -0.01 (-0.56%)
Volume: 243,646 @11/05/21 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.74 - 1.79
AIM Detailed Quote

https://www.otcmarkets.com/stock/AIM

AIM ImmunoTech Inc (AIM)
2.0001 ? -0.0699 (-3.38%)
Volume: 379,977 @09/22/21 7:19:50 PM EDT
Bid Ask Day's Range
- - 1.97 - 2.06
AIM Detailed Quote

AIM ImmunoTech Inc (AIM)
2.03 ? 0.03 (1.50%)
Volume: 239,934 @08/13/21 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.98 - 2.01
AIM Detailed Quote

Sign this petition for Ampligen approval

http://chng.it/ntCkN45ppP

Lovely 70g sell maybe news wed

AIM seems to have a hand off drug Ampligen, tested decades ago by other companies:
https://en.wikipedia.org/wiki/Rintatolimod

AIM may be in a chart ready technical phase ready to soar, and I am always ready to applaud the perfect timing of that thrilling prediction.

But in spite of that I recognize AIM's drug approval endeavors as proof of my 2 points:
........That no one can prove a drug will ever be a total failure. All studies of a drug may not have provided the proper conditions to test it for any ultimate endpoint statistical acceptance favoring FDA approval...... Other possible drug trials failures include:
Improper selection of the patients with the most susceptible bio markers.
Improper dosage.
Failure to dose after patient has been conditioned with other therapies as heat, cold, or in drug combination before or after the applications of the combination drug or cocktail.
Etc,etc, etc.
Armed with an infinity of possible reasons for a drug failure such a Company hires experts in PR's to promote the wording of forthcoming positive hopeful conclusions.....headline sound bites will make the stock rise, and the hired experts stand by with ready vigilance to float and dilute at the inflated prices, till stock falls under $1 on sell-offs, until new R/S's sizes it back to harken to the low float crowd, primed ready to continue serving the wash and rinse process, on hopes they can capture the meat before its ultimate trip on the conveyer belt of dreamy expectations, or total failure..